CLYM

Mizuho initiated coverage of Climb Bio with a rating of Outperform and set a new price target of $18.00

PRE 14A - Climb Bio, Inc. (0001768446) (Filer)

WELLESLEY HILLS, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced details for the next installment of their R&D Spotlight Series - a budoprutug webcast event, which is set for Tuesday, May 5, 2026, at 8:00 a.m. ET. The event will highlight the Company's budoprutug program, a clinical-stage, anti-CD19 monoclonal antibody with the potential to address a broad range of B-cell mediated, immune-driven diseases. Budoprutug is being evaluated in clinical trials for primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus

WELLESLEY HILLS, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to budoprutug, the company's investigational anti-CD19 monoclonal antibody, for the treatment of primary membranous nephropathy (pMN)—a rare kidney disease for which there are currently no FDA-approved treatments. "Fast Track Designation recognizes both the urgent need for new therapies in pMN and the compelling early clinical activity generated to date with budoprutug," said Edgar Charles, M.D.,

8-K - Climb Bio, Inc. (0001768446) (Filer)

B. Riley Securities initiated coverage of Climb Bio with a rating of Buy and set a new price target of $26.00

Truist initiated coverage of Climb Bio with a rating of Buy and set a new price target of $17.00

Raymond James initiated coverage of Climb Bio with a rating of Strong Buy and set a new price target of $25.00

Wedbush initiated coverage of Climb Bio with a rating of Outperform and set a new price target of $12.00

S-8 - Climb Bio, Inc. (0001768446) (Filer)

10-K - Climb Bio, Inc. (0001768446) (Filer)

8-K - Climb Bio, Inc. (0001768446) (Filer)

Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026 Budoprutug clinical trials ongoing in pMN, ITP, and SLE, with initial data from all three trials expected in H2 2026 Enrollment ongoing in CLYM116 Phase 1 healthy volunteer study, with initial data expected mid-2026 Strong financial position with cash runway expected into 2028 WELLESLEY HILLS, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided busines

4 - Climb Bio, Inc. (0001768446) (Issuer)

SCHEDULE 13G - Climb Bio, Inc. (0001768446) (Subject)

4 - Climb Bio, Inc. (0001768446) (Issuer)

Piper Sandler initiated coverage of Climb Bio with a rating of Overweight and set a new price target of $23.00

WELLESLEY HILLS, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that members of its executive team will participate in the upcoming conferences detailed below. Guggenheim's Emerging Outlook: Biotech SummitFormat: Fireside ChatDate: Thursday, February 12, 2026Time: 3:00 – 3:25 p.m. ET Oppenheimer 36th Annual Healthcare Life Sciences Conference Format: Fireside ChatDate: Wednesday, February 25, 2026Time: 1:20 – 1:50 p.m. ET Leerink Global Healthcare Conference Format: Fireside ChatDate: Monday, March 9, 2026Time: 2:20 – 2:50 p.m. ET The live

4 - Climb Bio, Inc. (0001768446) (Issuer)

4 - Climb Bio, Inc. (0001768446) (Issuer)

4 - Climb Bio, Inc. (0001768446) (Issuer)

4 - Climb Bio, Inc. (0001768446) (Issuer)

8-K - Climb Bio, Inc. (0001768446) (Filer)

First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026  Dosing ongoing in budoprutug Phase 1b/2a trial in ITP and Phase 1b trial in SLE; achieved regulatory clearance for SLE IND in China First patients dosed in CLYM116 Phase 1 healthy volunteer study Anticipating a data-rich 2026, with initial readouts from all ongoing budoprutug and CLYM116 studies Strong financial position with cash runway expected into 2028 WELLESLEY HILLS, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced progress upd

4 - Climb Bio, Inc. (0001768446) (Issuer)